文献速递临床试验与 GCP医学教育与科研方法

试验救援失败:急性护理环境中抗生素随机试验的经验教训

Failure to rescue the trial: lessons from a randomised antibiotic treatment trial in the acute care setting.
PubMed 文献 · Trials · 2026-04-23

一项评估头孢菌素单药治疗对脓毒症经验性治疗非劣效于头孢呋辛联合短程氨基糖苷类联合治疗的整群随机交叉试验,因入组率低和方案依从性低而因操作无效终止。本研究采用混合方法分析入组和治疗依从性的障碍。

要点

  • 入组主要障碍是排除标准比例高于预期(52.2%因至少一项排除标准被排除)。
  • 治疗依从性主要障碍是对联合治疗潜在副作用的担忧。
  • 建议在试验设计阶段进行定量和定性试点研究以优化招募和方案依从性。

核心结论

  • 患者入组的主要障碍是排除标准比例高于预期。
  • 治疗依从性的主要障碍是对联合治疗潜在副作用的担忧。
  • 建议在试验设计阶段进行定量和定性试点研究以识别障碍。

研究设计与样本

  • 混合方法研究,使用问卷调查当地研究团队和临床工作人员,并分析筛选日志。
  • 试验入组时间为2022年5月至2023年5月,问卷收集于2024年1月至3月。
  • 共完成65份问卷:23份来自当地研究团队成员,54份来自临床工作人员(包括12名当地研究团队成员)。

主要发现

  • 52.2%的患者因至少一项排除标准被排除。
  • 15.6%的合格患者拒绝同意参与研究。
  • 处方联合治疗的主要障碍是担心潜在副作用和认为相比单药治疗获益有限。
  • 次要障碍包括主管建议偏离研究方案。
  • 当地研究团队认为保持临床工作人员知情和培训是实施的相关障碍,但临床工作人员认为重要性低。

临床怎么用

  • 在试验设计阶段进行定量和定性试点研究以识别入组和依从性障碍。
  • 优化招募策略和方案依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A cluster-randomised cross-over trial assessing whether cephalosporin monotherapy is non-inferior to cefuroxime plus short-course aminoglycoside combination therapy for empirical sepsis treatment was terminated for operational futility due to low enrolment and low protocol adherence. We evaluated barriers to enrolment and treatment compliance. METHODS: Trial enrolment was between May 2022 and May 2023. For this mixed-methods study, we used questionnaires to identify barriers to enrolment and prescribing randomised treatment among local research teams (LRTs) and local clinical staff, which were obtained between January and March 2024. In addition, we investigated screening logs for non-enrolment reasons and determined patient characteristics associated with non-compliance. Clinicians being part of LRT received questionnaires for both roles, with their role clearly indicated per question. RESULTS: In total, 65 questionnaires were completed: 23 by LRT members and 54 by clinical staff (including 12 LRT members). For patient enrolment, screening of inclusion and exclusion criteria was considered challenging in one hospital. According to screening logs, 52.2% of patients were excluded due to at least one exclusion criterion, and 15.6% of eligible patients declined consent for study participation. Primary barriers to prescribe combination therapy were concerns about potential side effects and limited perceived benefit compared to monotherapy. Secondary barriers included supervisors recommending deviations from study protocol. Keeping clinical staff informed and trained during the study was reported as relevant barrier for implementation by LRTs, but considered of low importance by clinical staff. No barriers were reported for monotherapy. CONCLUSIONS: In this study, the main barrier for patient enrolment was the higher than expected proportion of patients with exclusion criteria. The main barrier for treatment compliance was concerns about potential side effects of combination therapy. We recommend quantitative and qualitative pilot studies to identify barriers during the trial design phase, to optimise recruitment strategies and protocol adherence. TRIAL REGISTRATION: European Union Clinical Trials Register, EUCTR2021-001840-83-NL. Registered on 7 July 2021, https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-001840-83.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. van den Eijnde SEJD, Koekenbier EL, van der Linden PD, et al. Failure to rescue the trial: lessons from a randomised antibiotic treatment trial in the acute care setting. Trials. 2026. PMID: 42026686. doi:10.1186/s13063-026-09722-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。